ArticleRadiology. Imaging cancer2026
Clinical Utility of Deep Learning-based Multiple Arterial Phase MRI in Hepatocellular Carcinoma.
Article in Radiology. Imaging cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deep Learning-based Multiple Arterial Phase MRI: A Step toward Improved Hepatocellular Carcinoma Diagnosis.Radiology. Imaging cancer · 2026Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose To evaluate the clinical utility of deep learning-based ultrafast multiple arterial phase (AP) MRI for diagnosing hepatocellular carcinoma (HCC), compared with conventional single AP imaging, using both extracellular agents (ECAs) and hepatobiliary agents (HBAs). Materials and Methods This prospective study included participants with suspected HCC who underwent either ECA- or HBA-enhanced MRI between September 2024 and March 2025. Outcomes included late AP capture rate, image quality (overall quality, motion artifacts, noise, liver and lesion edge sharpness, and lesion conspicuity), diagnostic performance (lesion, arterial phase hyperenhancement [APHE], and HCC detection rates), and hepatic arterial visualization scoring. Wilcoxon rank sum, Pearson χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.